US Bancorp DE Buys 25,692 Shares of Genmab A/S Sponsored ADR $GMAB

US Bancorp DE grew its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 29.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 113,850 shares of the company’s stock after acquiring an additional 25,692 shares during the quarter. US Bancorp DE’s holdings in Genmab A/S were worth $3,492,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of GMAB. Advyzon Investment Management LLC bought a new stake in Genmab A/S in the third quarter valued at approximately $216,000. Citigroup Inc. raised its stake in Genmab A/S by 13.0% during the 3rd quarter. Citigroup Inc. now owns 98,818 shares of the company’s stock worth $3,031,000 after buying an additional 11,347 shares during the period. NewEdge Wealth LLC bought a new position in Genmab A/S during the third quarter worth about $346,000. Syon Capital LLC acquired a new position in Genmab A/S in the third quarter valued at about $226,000. Finally, NEOS Investment Management LLC grew its stake in Genmab A/S by 1.4% in the third quarter. NEOS Investment Management LLC now owns 132,043 shares of the company’s stock valued at $4,050,000 after acquiring an additional 1,826 shares during the period. Institutional investors own 7.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. HC Wainwright raised their price target on Genmab A/S from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Wells Fargo & Company assumed coverage on shares of Genmab A/S in a report on Monday. They set an “overweight” rating and a $40.00 target price on the stock. Guggenheim reduced their price target on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a report on Monday, February 23rd. Wall Street Zen downgraded shares of Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, Morgan Stanley started coverage on shares of Genmab A/S in a research report on Monday, February 16th. They issued an “equal weight” rating and a $34.00 price objective on the stock. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.58.

Genmab A/S Stock Performance

Shares of GMAB opened at $27.66 on Wednesday. The stock has a market capitalization of $17.77 billion, a price-to-earnings ratio of 17.85, a PEG ratio of 1.22 and a beta of 0.94. Genmab A/S Sponsored ADR has a 12 month low of $17.24 and a 12 month high of $35.43. The firm has a fifty day simple moving average of $31.72 and a 200 day simple moving average of $30.37. The company has a current ratio of 2.02, a quick ratio of 2.01 and a debt-to-equity ratio of 0.86.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Tuesday, February 17th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.41). The business had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%. Research analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.